Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
BEVERLY, Mass. and TORONTO, May 01, 2018 -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that David Wolf, President and CEO of Hamilton Thorne Ltd., will present at the 2018 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Hotel Toronto on Thursday May 3, 2018 at 11:00 a.m. Eastern Time.
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly
traded and private companies through presentations and private meetings.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact:
David Wolf, President & CEO
Hamilton Thorne Ltd.
978-921-2050
[email protected]
Michael Bruns, CFO
Hamilton Thorne Ltd.
978-921-2050
[email protected]
Glen Akselrod
Bristol Investor Relations
905-326-1888
[email protected]
